GlassScriptPhysician profile
Johnathan M Raskin
NPI 1538156989
$337,534.06
in general payments reported to CMS, 2019-2025
29 companies · $35K in 2025
The $35K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $48K · 2021: $34K · 2022: $36K · 2023: $76K · 2024: $38K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $132K · Food and Beverage: $10K · Travel and Lodging: $6,199 · Education: $103 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $131,623.80 |
| Food and Beverage | $10,089.48 |
| Travel and Lodging | $6,198.53 |
| Education | $102.77 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $314,882.58 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $7,055.99 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $4,306.22 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,965.78 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Mylan Specialty L.P. | $2,003.36 | 2019 | |
| Insmed, INC. | $1,207.55 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $1,093.41 | 2019-2025 | |
| Amgen INC. | $431.23 | 2021-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $389.54 | 2020-2022 | |
| Lilly USA, LLC | $313.30 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Grifols USA, LLC | $284.39 | 2020-2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $247.90 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $229.57 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $214.55 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.44 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $138.20 | 2019-2024 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $98.64 | 2019-2021 | |
| Pfizer INC. | $73.13 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $64.69 | 2025 | Opsynvi |
| Verona Pharma, INC. | $62.75 | 2025 | Ohtuvayre |
| Covis Pharma Gmbh | $61.14 | 2021-2022 | |
| Novo Nordisk INC | $55.63 | 2024 | Ozempic, Rybelsus |
| Pulmonx Corporation | $46.65 | 2023 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Sanofi Pasteur INC. | $39.58 | 2019-2020 | |
| Abbvie INC. | $30.65 | 2019 | |
| Vifor Pharma, INC. | $24.56 | 2025 | Zemaira |
| Idorsia Pharmaceuticals US INC | $20.10 | 2023 | Quviviq |
| Alexion Pharmaceuticals, INC. | $19.94 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathan Raskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.